NCT03168815Active, not recruiting
Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy
Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 9 May 2025
Brief summary (registry, in English)
Pneumonia is a lung infection. Fiberoptic bronchoscopy is a test to diagnose the type of lung infection. While this procedure is being performed, a small amount of oxygen is delivered into the nose (low flow nasal cannula). Occasionally during this procedure, the blood oxygen of the patient may drop and an intervention such as increasing the oxygen flow, or placing the patient on a breathing machine is required. An alternative device called 'Optiflow' can provide high flow oxygen through nasal cannula, and is comfortable for patients. If Optiflow is used during bronchoscopy, it may prevent the blood oxygen from dropping.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- First submitted
- 24 May 2017
- Start date
- 10 Jan 2018
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Mount Sinai Hospital, Canada
- NCT number
- NCT03168815
What you commit to
- Study type: Interventional
- Planned participants: 98
- From 10 Jan 2018 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- receiving HFNC before randomization;
Other
- requiring supplemental oxygen \> 8L/min by nasal cannula;
- nasal deformity or packing precluding HFNC use;
- hypercapnia (PaCO2 \> 60) or respiratory acidosis (pH \<7.25);
- requiring NIV for over 1 hour or intubated.
Who the study is looking for
- Adult patients ≥18 years scheduled to undergo FOB (as determined by their medical care team) who are immunocompromised (active hematologic malignancy or post hematopoietic stem cell transplant), and are hypoxic with pulmonary infiltrates. Hypoxia will be defined as requiring supplemental low flow oxygen ≥ 2L/min by nasal cannula to maintain SpO2 \>90%.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mount Sinai Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.